{
    "pmcid": "10688893",
    "qa_pairs": {
        "How does Nb-021 neutralize the SARS-CoV-2 virus according to the study?": [
            "By destabilizing the spike protein's pre-fusion conformation",
            "By directly competing with ACE2 for binding",
            "By enhancing the spike protein's fusion conformation",
            "By binding to the ACE2 receptor directly"
        ],
        "What are the key properties of nanobodies that make them attractive for therapeutic applications against viral infections like SARS-CoV-2?": [
            "Small size, high stability, solubility, and ease of production",
            "Large size, high stability, solubility, and complex production",
            "Small size, low stability, insolubility, and ease of production",
            "Large size, low stability, insolubility, and complex production"
        ],
        "What challenge related to SARS-CoV-2 variants does the study address in the context of nanobody efficacy?": [
            "Variants escaping neutralization due to mutations in the S-RBD",
            "Variants enhancing neutralization due to mutations in the S-RBD",
            "Variants reducing neutralization due to mutations in the N-RBD",
            "Variants escaping neutralization due to mutations in the N-RBD"
        ],
        "What is the composition of the bispecific nanobody conjugate Nb-X2-Fc mentioned in the study?": [
            "Nb-015 and Nb-021 linked with an IgG1 Fc tag",
            "Nb-101 and Nb-202 linked with an IgG2 Fc tag",
            "Nb-050 and Nb-060 linked with an IgG3 Fc tag",
            "Nb-301 and Nb-401 linked with an IgG4 Fc tag"
        ],
        "Which two high-affinity nanobodies were isolated from an immunized alpaca for targeting the SARS-CoV-2 spike receptor-binding domain?": [
            "Nb-015 and Nb-021",
            "Nb-101 and Nb-202",
            "Nb-050 and Nb-060",
            "Nb-301 and Nb-401"
        ]
    }
}